Valuation: C4 Therapeutics, Inc.

Market Cap 463M 406M 375M 347M 657M 44.36B 670M 4.51B 1.75B 21.71B 1.74B 1.7B 75.36B P/E 2026 *
-4.48x
P/E 2027 * -4.16x
Enterprise Value 463M 406M 375M 347M 657M 44.36B 670M 4.51B 1.75B 21.71B 1.74B 1.7B 75.36B EV / Sales 2026 *
24.5x
EV / Sales 2027 * 24.2x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day-3.68%
1 week-3.46%
Current month-10.28%
1 month+16.71%
3 months+44.48%
6 months+91.32%
Current year+119.37%
1 week 3.72
Extreme 3.725
4.42
1 month 3.53
Extreme 3.53
5.17
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
51.21
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 2020-10-01
Director of Finance/CFO 49 2023-09-17
Chief Tech/Sci/R&D Officer 56 2024-10-27
Director TitleAgeSince
Director/Board Member 74 2015-11-30
Director/Board Member 55 2020-09-13
Director/Board Member 55 2022-03-15
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Founder

2,650 0.0024%
06-30Free

Director

3,341 0.0030%
06-23Free

Director

62,000 0.0561%
Change 5-day change 1-year change 3-year change Capi.($)
-3.68%-3.46%+145.03%+24.33% 463M
+0.51%+1.88%+2.24%+8.82% 49.42B
-0.36%+1.21%+420.77%+619.10% 40.34B
-2.13%+0.29%+23.91%-6.01% 34.01B
-2.29%+3.83%+23.48%+59.26% 33.56B
-0.79%+1.32%+5.78%+36.42% 26.84B
+3.82%+3.51% - - 17.22B
-2.62%-2.13%+64.96%+125.87% 15.19B
-2.17%+6.65%+104.31%+102.15% 13.96B
+0.48%-2.52%+12.86%+18.34% 13.36B
Average -2.99%+0.98%+89.26%+109.81% 24.44B
Weighted average by Cap. -1.84%+1.53%+94.76%+139.86%

Financials

2026 *2027 *
Net sales 18.92M 16.6M 15.32M 14.16M 26.84M 1.81B 27.38M 184M 71.58M 887M 71.07M 69.51M 3.08B 19.14M 16.79M 15.5M 14.32M 27.15M 1.83B 27.69M 186M 72.4M 897M 71.88M 70.3M 3.11B
Net income -119M -105M -96.51M -89.18M -169M -11.41B -172M -1.16B -451M -5.58B -448M -438M -19.39B -151M -132M -122M -113M -214M -14.43B -218M -1.47B -570M -7.06B -566M -554M -24.52B
Net Debt - -
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
26-07-08 US$4.190 -3.68% 6,712,598
26-07-07 US$4.350 +5.07% 4,373,751
26-07-06 US$4.140 -3.72% 1,904,782
26-07-02 US$4.300 -0.92% 2,624,634
26-07-01 US$4.340 -7.07% 5,353,038
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.190USD
Average target price
13.33USD
Spread / Average Target
+218.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CCCC Stock